US FDA panel votes for ALS drug Amylyx







Illustration shows Amylyx logo

Amylyx Pharmaceuticals Inc’s drug for amyotrophic lateral sclerosis (ALS) won the backing of external advisers from the US Food and Drug Administration on Wednesday.

The FDA panel voted 7 to 2 in favor of the oral drug, AMX0035, citing the unmet need for more treatments for the deadly neurodegenerative disease commonly known as Lou Gehrig’s disease.

Marketzone with Reuters 2022

All the news about AMYLYX PHARMACEUTICALS, INC.

Analyst Recommendations for AMYLYX PHARMACEUTICALS, INC.

2022 turnover 3.36M
–
3.37M
2022 net result -197M
–
-198M
trso. net 2022 1.50M
–
1.51M
PER 2022-5.11x
2022 return–
Capitalization 1,048M
1,048M
1,053M
VE / CA 2022312x
VE / CA 20237.00x
Number of employees226
Floating69.8%

Chart AMYLYX PHARMACEUTICALS, INC.


Hard :

Period:




Amylyx Pharmaceuticals, Inc. : Chart technical analysis Amylyx Pharmaceuticals, Inc. | Market area

Trends Technical Analysis AMYLYX PHARMACEUTICALS, INC.

Short termMiddle termLong term
TrendsbearishNeutralNeutral

Evolution of the Income Statement

Sale

Purchase

Average recommendationTO BUY
Number of Analysts5
Last Closing Price$17.90
Average price target$30.75
Deviation / Average Target71.8%

Officers and Directors




Source link -88